Quantitative measurements of p95HER2 (p95) protein expression in tumors from patients with metastatic breast cancer (MBC) treated with trastuzumab: Independent confirmation of the p95 clinical cutoff.

Renata Duchnowska,Jeff Sperinde,Mojgan Haddad,Ahmed Chenna,A. Paquet,Yolanda Lie,Jodi Weidler,Weidong Huang,John Winslow,T. Jankowski,Bogumiła Czartoryska-Arłukowicz,Piotr Jan Wysocki,M Foszczynska-Kloda,Barbara Radecka,Maria Litwiniuk,J Zok,Michał Wiśniewski,Dorota Zuziak,Wojciech Biernat,Jacek Jassem

Quantitative measurements of p95HER2 (p95) protein expression in tumors from patients with metastatic breast cancer (MBC) treated with trastuzumab: Independent confirmation of the p95 clinical cutoff.

2017

604 Background: Expression of p95 in HER2-positive breast cancer is potentially a major determinant of trastuzumab resistance because p95 lacks the trastuzumab binding site while retaining kinase a...

Keywords:

Pathology
Breast cancer
Kinase
Cancer research
Trastuzumab
Binding site
Protein expression
Cutoff
Medicine
Metastatic breast cancer
trastuzumab resistance

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations